Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Century Therapeutics, Inc. (IPSC)
USD2.12
-0.01 (-0.48%)
US NASDAQ Healthcare Biotechnology
Address
3675 Market Street 19104
Philadelphia, PA, US
Philadelphia, PA, US
CEO
Brent Pfeiffenberger
Website
centurytx.com
IPO
2021-06-18
CIK 1850119 ISIN US15673T1007
Description
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.12
-0.01 (-0.48%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.57
Float Shares
48.65M
Free Float %
56.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.39% | +3.48% | +0.42% | +36.00% | +403.92% | +139.24% | +386.61% | -28.10% | -89.58% | -89.58% | -89.58% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
2.12
Low
2.00
-5.7%
Consensus
3.00
+41.5%
Median
3.00
+41.5%
High
4.00
+88.7%
DCF (Unlevered)
2.31
+8.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
2.00
-5.7%
|
| Last Year | 2 |
3.00
+41.5%
|
| All Time | 8 |
13.13
+519.4%
|
Quality scores
Altman Z-Score
-2.24
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+1,556.8% ★ Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+93.2% ★ Q1'26: -112.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-107.4%
-
EBIT margin Biotechnology: +0.0%-13.8%
-
ROIC Biotechnology: -16.1%-17.6% Q1'26: -58.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+10.1% Q1'26: +124.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-22.47× Q1'26: -0.49× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.20M
est: 6.69M (-22.3%)
|
2.24M
est: 2.04M (+9.5%)
|
6.59M
est: 3.19M (+106.5%)
|
109.16M
est: 109.18M (0.0%)
|
4.72M
4.72M – 4.72M
-95.7% YoY
|
3.74M
3.74M – 3.74M
-20.9% YoY
|
1.18M
1.18M – 1.18M
-68.4% YoY
|
375.0K
375.0K – 375.0K
-68.2% YoY
|
77.60M
77.60M – 77.60M
+20,593.3% YoY
|
| EBITDA |
-121.20M
est: -1.34M (-8,958.0%)
|
-121.21M
est: -823.7K (-14,616.0%)
|
-111.47M
est: -1.29M (-8,557.6%)
|
-1.94M
est: -44.06M (+95.6%)
|
-1.91M
-1.91M – -1.91M
+95.7% YoY
|
-1.51M
-1.51M – -1.51M
+20.9% YoY
|
-476.2K
-476.2K – -476.2K
+68.4% YoY
|
-151.3K
-151.3K – -151.3K
+68.2% YoY
|
-31.32M
-31.32M – -31.32M
-20,593.4% YoY
|
| EBIT |
-129.64M
est: -1.34M (-9,588.7%)
|
-134.25M
est: -872.6K (-15,284.6%)
|
-124.78M
est: -1.36M (-9,046.8%)
|
-15.04M
est: -46.68M (+67.8%)
|
-2.02M
-2.02M – -2.02M
+95.7% YoY
|
-1.60M
-1.60M – -1.60M
+20.9% YoY
|
-504.5K
-504.5K – -504.5K
+68.4% YoY
|
-160.3K
-160.3K – -160.3K
+68.2% YoY
|
-33.18M
-33.18M – -33.18M
-20,593.3% YoY
|
| Net Income |
-130.93M
est: -181.52M (+27.9%)
|
-136.67M
est: -172.42M (+20.7%)
|
-126.57M
est: -137.28M (+7.8%)
|
-9.58M
est: -17.41M (+45.0%)
|
-60.16M
-86.56M – -33.76M
-245.5% YoY
|
-49.76M
-72.60M – -26.92M
+17.3% YoY
|
-37.22M
-43.50M – -30.94M
+25.2% YoY
|
-43.57M
-43.57M – -43.57M
-17.1% YoY
|
-33.76M
-33.76M – -33.76M
+22.5% YoY
|
| SGA |
31.86M
est: 38.39M (-17.0%)
|
34.71M
est: 11.39M (+204.7%)
|
33.16M
est: 17.81M (+86.2%)
|
24.00M
est: 609.40M (-96.1%)
|
26.36M
26.36M – 26.36M
-95.7% YoY
|
20.85M
20.85M – 20.85M
-20.9% YoY
|
6.59M
6.59M – 6.59M
-68.4% YoY
|
2.09M
2.09M – 2.09M
-68.2% YoY
|
433.13M
433.13M – 433.13M
+20,593.3% YoY
|
| EPS |
-2.27
est: -2.31 (+1.6%)
|
-2.30
est: -1.99 (-15.5%)
|
-1.61
est: -1.62 (+0.4%)
|
-0.11
est: -0.18 (+38.9%)
|
-0.63
-1.00 – -0.39
-250.0% YoY
|
-0.56
-0.84 – -0.31
+11.7% YoY
|
-0.43
-0.50 – -0.36
+22.7% YoY
|
-0.50
-0.50 – -0.50
-17.1% YoY
|
-0.39
-0.39 – -0.39
+22.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-21 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-522.77M
OE per share TTM
-3.29
Owner's Yield
-113.53%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
372.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
15
Total invested
42.70M
Insider transactions (90d)
1
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bayer Aktiengesellschaft | 12.68M | 23.20% | — | — | — | 12.68M | HC, CO | Citizenship or Place of Organization | 2022-02-11 | ↗ |
| 2 | Bayer World Investments B.V. | 12.68M | 23.20% | — | — | — | 12.68M | CO | Citizenship or Place of Organization | 2022-02-11 | ↗ |
| 3 | GP-GP, | 12.37M | 22.60% | — | 12.37M | — | 12.37M | OO | — | 2022-02-11 | ↗ |
| 4 | Versant Venture Capital VI, L.P. | 12.37M | 22.60% | 12.37M | — | 12.37M | — | PN | — | 2022-02-11 | ↗ |
| 5 | Versant Ventures VI GP, L.P. | 12.37M | 22.60% | — | 12.37M | — | 12.37M | PN | — | 2022-02-11 | ↗ |
| 6 | FUJIFILM Cellular Dynamics, Inc. | 6.96M | 12.70% | 6.96M | — | 6.96M | — | CO | Wisconsin | 2022-02-11 | ↗ |
| 7 | FUJIFILM Corporation | 6.96M | 12.70% | 6.96M | — | 6.96M | — | HC, CO | Wisconsin | 2022-02-11 | ↗ |
| 8 | FUJIFILM Holdings America Corporation | 6.96M | 12.70% | 6.96M | — | 6.96M | — | HC, CO | Wisconsin | 2022-02-11 | ↗ |
| 9 | FUJIFILM Holdings Corporation | 6.96M | 12.70% | 6.96M | — | 6.96M | — | HC, CO | Wisconsin | 2022-02-11 | ↗ |
| 10 | Bain Capital Life Sciences Opportunities III, LP | 5.32M | 6.60% | — | 5.32M | — | 5.32M | PN | Delaware | 2024-04-25 | ↗ |
| 11 | Boxer Asset Management Inc. | 4.90M | 5.80% | — | 4.90M | — | 4.90M | CO | Delaware | 2024-04-22 | ↗ |
| 12 | Boxer Capital, LLC | 4.90M | 5.80% | — | 4.90M | — | 4.90M | OO | Delaware | 2024-04-22 | ↗ |
| 13 | Joe Lewis | 4.90M | 5.80% | — | 4.90M | — | 4.90M | IN | Delaware | 2024-04-22 | ↗ |
| 14 | Casdin Capital, LLC | 4.59M | 5.40% | — | 4.59M | — | 4.59M | IA | Delaware | 2024-11-27 | ↗ |
| 15 | Eli Casdin | 4.59M | 5.40% | — | 4.59M | — | 4.59M | HC, IN | Delaware | 2024-11-27 | ↗ |
| 16 | Koh, Bong | 3.41M | 5.40% | — | 3.41M | — | 3.41M | IN | Delaware | 2024-03-04 | ↗ |
| 17 | Shah, Nimish | 3.41M | 5.40% | — | 3.41M | — | 3.41M | IN | Delaware | 2024-03-04 | ↗ |
| 18 | VHCP Co-Investment Holdings III, LLC | 3.41M | 5.40% | — | 3.41M | — | 3.41M | OO | Delaware | 2024-03-04 | ↗ |
| 19 | VHCP Management EG, LLC | 3.41M | 5.40% | — | 3.41M | — | 3.41M | OO | Delaware | 2024-03-04 | ↗ |
| 20 | VHCP Management III, LLC | 3.41M | 5.40% | — | 3.41M | — | 3.41M | OO | Delaware | 2024-03-04 | ↗ |
| 21 | Venrock Healthcare Capital Partners EG, L.P. | 3.41M | 5.40% | — | 3.41M | — | 3.41M | PN | Delaware | 2024-03-04 | ↗ |
| 22 | Venrock Healthcare Capital Partners III, L.P. | 3.41M | 5.40% | — | 3.41M | — | 3.41M | PN | Delaware | 2024-03-04 | ↗ |
| 23 | Versant Vantage II GP, L.P. | 714.1K | 1.30% | — | 714.1K | — | 714.1K | PN | — | 2022-02-11 | ↗ |
| 24 | Versant Vantage II, L.P. | 714.1K | 1.30% | 714.1K | — | 714.1K | — | PN | — | 2022-02-11 | ↗ |
| 25 | Aaron I. Davis | 178.6K | 0.20% | — | 178.6K | — | 178.6K | IN | Delaware | 2024-04-22 | ↗ |
| 26 | MVA Investors, LLC | 178.6K | 0.20% | — | 178.6K | — | 178.6K | OO | Delaware | 2024-04-22 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
15
-31 vs prev Q
New positions
9
Closed positions
40
Increased
10
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1.42M +1.4M (+100.0%) | 1.41B +1.4B (+100.0%) | 1.64% +1.644 pp | 0.47% +0.467 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 2 | POINT72 ASSET MANAGEMENT, L.P. | 5.96M +6.0M (+100.0%) | 5.93M +5.9M (+100.0%) | 6.89% +6.895 pp | 0.01% +0.007 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 3 | DAFNA CAPITAL MANAGEMENT LLC | 2.79M +1.1M (+63.9%) | 2.78M +1.9M (+227.4%) | 3.23% +1.255 pp | 0.65% +0.436 pp | USD4.08 -75.7% | 19 qtrs — |
| 4 | VANGUARD GROUP INC | 2.10M +— (+0.0%) | 2.09M +1.0M (+99.8%) | 2.43% -0.006 pp | 0.00% +0.000 pp | USD8.56 -88.4% | 19 qtrs — |
| 5 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.84M +1.8M (+100.0%) | 1.83M +1.8M (+100.0%) | 2.13% +2.127 pp | 0.00% +0.003 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 6 | TWO SIGMA INVESTMENTS, LP | 1.50M +584.5K (+64.1%) | 1.49M +1.0M (+227.9%) | 1.73% +0.673 pp | 0.00% +0.001 pp | USD0.73 +35.6% | 5 qtrs — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 1.35M -1.2M (-47.8%) | 1.34M +53.9K (+4.2%) | 1.56% -1.439 pp | 0.00% +0.000 pp | USD1.01 -2.0% | 13 qtrs — |
| 8 | TWO SIGMA ADVISERS, LP | 1.27M +410.1K (+47.8%) | 1.26M +834.0K (+195.3%) | 1.47% +0.472 pp | 0.00% +0.002 pp | USD0.69 +43.5% | 5 qtrs — |
| 9 | CASDIN CAPITAL, LLC | 1.23M +— (+0.0%) | 1.22M +610.2K (+99.8%) | 1.42% -0.004 pp | 0.08% +0.025 pp | USD12.17 -91.9% | 19 qtrs — |
| 10 | ACADIAN ASSET MANAGEMENT LLC | 1.22M +497.3K (+69.1%) | 1.21M +852.0K (+238.7%) | 1.41% +0.573 pp | 0.00% +0.001 pp | USD0.83 +19.3% | 6 qtrs — |
| 11 | SYNCONA PORTFOLIO LTD | 1.21M +— (+0.0%) | 1.21M +602.9K (+99.8%) | 1.40% -0.004 pp | 3.52% +1.338 pp | USD2.29 -56.8% | 7 qtrs — |
| 12 | MILLENNIUM MANAGEMENT LLC | 610.4K -133.4K (-17.9%) | 607.2K +236.8K (+63.9%) | 0.71% -0.157 pp | 0.00% +0.000 pp | USD0.56 +76.8% | 15 qtrs — |
| 13 | BLACKROCK, INC. | 601.9K +2.2K (+0.4%) | 598.7K +300.1K (+100.5%) | 0.70% +0.001 pp | 0.00% +0.000 pp | USD1.70 -41.8% | 6 qtrs — |
| 14 | SUPERSTRING CAPITAL MANAGEMENT LP | 463.0K +— (+0.0%) | 460.6K +230.0K (+99.8%) | 0.54% -0.001 pp | 0.25% +0.019 pp | USD1.01 -2.0% | 5 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 456.1K +10.8K (+2.4%) | 453.9K +232.1K (+104.6%) | 0.53% +0.011 pp | 0.00% +0.000 pp | USD7.53 -86.9% | 19 qtrs — |
| 16 | GSA CAPITAL PARTNERS LLP | 333.2K -270.3K (-44.8%) | 331.0K +30.0K (+10.0%) | 0.39% -0.314 pp | 0.03% +0.003 pp | USD0.54 +83.3% | 3 qtrs — |
| 17 | CITADEL ADVISORS LLC | 319.5K -41.4K (-11.5%) | 317.8K +138.1K (+76.9%) | 0.37% -0.049 pp | 0.00% +0.000 pp | USD0.54 +83.3% | 18 qtrs — |
| 18 | UBS GROUP AG | 214.5K +214.2K (+63,550.1%) | 213.4K +213.3K (+126,940.5%) | 0.25% +0.248 pp | 0.00% +0.000 pp | USD1.00 -1.0% | 13 qtrs — |
| 19 | STATE STREET CORP | 127.4K +— (+0.0%) | 126.8K +63.3K (+99.8%) | 0.15% 0.000 pp | 0.00% +0.000 pp | USD8.27 -88.0% | 18 qtrs — |
| 20 | NORTHERN TRUST CORP | 105.1K +38.1K (+56.8%) | 104.5K +71.1K (+213.2%) | 0.12% +0.044 pp | 0.00% +0.000 pp | USD6.72 -85.3% | 18 qtrs — |
| 21 | RAYMOND JAMES FINANCIAL INC | 91.3K +— (+0.0%) | 90.8K +45.4K (+99.8%) | 0.11% 0.000 pp | 0.00% +0.000 pp | USD0.56 +76.8% | 3 qtrs — |
| 22 | ALGERT GLOBAL LLC | 76.8K +76.8K (+100.0%) | 76.0K +76.0K (+100.0%) | 0.09% +0.089 pp | 0.00% +0.001 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 23 | FMR LLC | 71.5K -120.6K (-62.8%) | 71.2K -24.5K (-25.6%) | 0.08% -0.140 pp | 0.00% +0.000 pp | USD26.83 -96.3% | 19 qtrs — |
| 24 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 77.8K -56.0 (-0.1%) | 70.0K +26.5K (+61.0%) | 0.09% 0.000 pp | 0.00% +0.000 pp | USD2.63 -62.4% | 10 qtrs — |
| 25 | PRUDENTIAL FINANCIAL INC | 59.8K +— (+0.0%) | 59.5K +29.7K (+99.8%) | 0.07% 0.000 pp | 0.00% +0.000 pp | USD0.54 +83.3% | 8 qtrs — |
| 26 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 50.1K -17.8K (-26.2%) | 49.8K +16.0K (+47.4%) | 0.06% -0.021 pp | 0.00% +0.000 pp | USD0.62 +59.7% | 5 qtrs — |
| 27 | JANE STREET GROUP, LLC | 45.2K -13.5K (-23.1%) | 45.0K +15.7K (+53.7%) | 0.05% -0.016 pp | 0.00% +0.000 pp | USD0.56 +76.8% | 9 qtrs — |
| 28 | HARBOURVEST PARTNERS LLC | 29.0K +— (+0.0%) | 28.9K +14.4K (+99.8%) | 0.03% 0.000 pp | 0.02% +0.010 pp | USD12.90 -92.3% | 17 qtrs — |
| 29 | PARAMETRICA MANAGEMENT LTD | 27.8K +— (+0.0%) | 27.7K +13.8K (+99.8%) | 0.03% 0.000 pp | 0.04% +0.021 pp | USD8.40 -88.2% | 18 qtrs — |
| 30 | XTX TOPCO LTD | 15.3K -12.2K (-44.4%) | 15.3K +1.5K (+11.1%) | 0.02% -0.014 pp | 0.00% 0.000 pp | USD0.50 +98.0% | 5 qtrs — |
| 31 | QUADRANT PRIVATE WEALTH MANAGEMENT, LLC | 15.3K +— (+0.0%) | 15.2K +7.6K (+99.8%) | 0.02% +0.000 pp | 0.00% +0.001 pp | USD0.56 +76.8% | 3 qtrs — |
| 32 | SCIENTECH RESEARCH LLC | 12.4K +12.4K (+100.0%) | 12.3K +12.3K (+100.0%) | 0.01% +0.014 pp | 0.01% +0.008 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 33 | ADVISORS ASSET MANAGEMENT, INC. | 8.3K -99.0 (-1.2%) | 8.3K +4.1K (+97.4%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD0.56 +76.8% | 3 qtrs — |
| 34 | JPMORGAN CHASE & CO | 3.1K +1.5K (+93.2%) | 3.1K +2.3K (+286.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD1.71 -42.1% | 18 qtrs — |
| 35 | SIMPLEX TRADING, LLC | 2.4K +2.4K (+100.0%) | 2.4K +2.4K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 36 | SBI SECURITIES CO., LTD. | 1.5K +— (+0.0%) | 1.5K +760.0 (+99.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.59 +67.8% | 5 qtrs — |
| 37 | BNP PARIBAS ARBITRAGE, SNC | 1.4K -31.0 (-2.1%) | 1.4K +703.0 (+95.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.01 -2.0% | 5 qtrs — |
| 38 | NISA INVESTMENT ADVISORS, LLC | 883.00 +— (+0.0%) | 878.00 +438.0 (+99.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.71 +39.4% | 11 qtrs — |
| 39 | BANK OF AMERICA CORP /DE/ | 525.00 -73.0 (-12.2%) | 522.00 +224.0 (+75.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD5.78 -82.9% | 18 qtrs — |
| 40 | MARK SHEPTOFF FINANCIAL PLANNING, LLC | 500.00 +— (+0.0%) | 497.00 +248.0 (+99.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.71 -42.1% | 6 qtrs — |
| 41 | SRS CAPITAL ADVISORS, INC. | 99.00 +— (+0.0%) | 98.00 +49.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.49 +102.0% | 2 qtrs — |
| 42 | WELLS FARGO & COMPANY/MN | 40.00 +40.0 (+100.0%) | 40.00 +40.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.98 +1.0% | 18 qtrs — |
| 43 | OPTIVER HOLDING B.V. | 32.00 +— (+0.0%) | 32.00 +16.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.47 +110.6% | 2 qtrs — |
| 44 | BARCLAYS PLC | 1.00 -61.9K (-100.0%) | 1.00 -105.9K (-100.0%) | 0.00% -0.072 pp | 0.00% +0.000 pp | USD— | 16 qtrs — |
| 45 | SMARTLEAF ASSET MANAGEMENT LLC | 1.00 +1.0 (+100.0%) | 1.00 +1.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 1 qtrs NEW |
| 46 | CITIGROUP INC | 1.00 -2.2K (-100.0%) | 1.00 -1.1K (-99.9%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD2.00 -50.5% | 18 qtrs — |
| 47 | TANG CAPITAL MANAGEMENT LLC | — -900.0K (-100.0%) | — -448.2K (-100.0%) | 0.00% -1.044 pp | 0.00% -0.017 pp | USD— | 9 qtrs SOLD |
| 48 | TOWER RESEARCH CAPITAL LLC (TRC) | — -13.1K (-100.0%) | — -6.5K (-100.0%) | 0.00% -0.015 pp | 0.00% 0.000 pp | USD— | 18 qtrs SOLD |
| 49 | AQR CAPITAL MANAGEMENT LLC | — -10.7K (-100.0%) | — -5.3K (-100.0%) | 0.00% -0.012 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 50 | GOLDMAN SACHS GROUP INC | — -60.7K (-100.0%) | — -30.2K (-100.0%) | 0.00% -0.070 pp | 0.00% +0.000 pp | USD— | 19 qtrs SOLD |
| 51 | EVERSOURCE WEALTH ADVISORS, LLC | — -28.0 (-100.0%) | — -14.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 52 | ADVISORY SERVICES NETWORK, LLC | — -407.0 (-100.0%) | — -203.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 53 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | — -3.5M (-100.0%) | — -1.8M (-100.0%) | 0.00% -4.103 pp | 0.00% -0.117 pp | USD— | 7 qtrs SOLD |
| 54 | MORGAN STANLEY | — -118.0 (-100.0%) | — -59.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 19 qtrs SOLD |
| 55 | QUBE RESEARCH & TECHNOLOGIES LTD | — -17.5K (-100.0%) | — -8.7K (-100.0%) | 0.00% -0.020 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 56 | MARSHALL WACE, LLP | — -54.2K (-100.0%) | — -27.1K (-100.0%) | 0.00% -0.063 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 57 | SQUAREPOINT OPS LLC | — -236.1K (-100.0%) | — -117.6K (-100.0%) | 0.00% -0.274 pp | 0.00% 0.000 pp | USD— | 6 qtrs SOLD |
| 58 | JAIN GLOBAL LLC | — -11.2K (-100.0%) | — -5.6K (-100.0%) | 0.00% -0.013 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 59 | IFP ADVISORS, INC | — -6.0 (-100.0%) | — -3.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 60 | HRT FINANCIAL LP | — -18.1K (-100.0%) | — -9.0K (-100.0%) | 0.00% -0.021 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 44 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.18% | 499.6K | 0.39% |
| 2 | iShares Micro-Cap ETF IWC | 0.06% | 930.0K | 0.60% |
| 3 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 278.8K | 0.20% |
| 4 | iShares Russell 2000 Value ETF IWN | 0.02% | 2.46M | 0.24% |
| 5 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 394.3K | 0.25% |
| 6 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 269.7K | 0.30% |
| 7 | Global X - Russell 2000 ETF RSSL | 0.01% | 129.1K | 0.08% |
| 8 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 28.0K | 0.25% |
| 9 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 4.6K | 0.39% |
| 10 | iShares Russell 2000 ETF IWM | 0.01% | 6.66M | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
1.6K
Cash buys
—
Cash sales
1.00
Net activity
-1,629
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Carr Douglas | Officer | S-Sale | D | Common Stock | 264 | 2.34 | 618.02 | 506,997 | D | ↗ |
| 2026-04-01 | Cowan Chad | Officer | F-InKind | D | Common Stock | 1,365 | 2.19 | 3.0K | 1,175,680 | D | ↗ |
| 2026-03-12 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 10,076 | 2.55 | 25.7K | 515,427 | D | ↗ |
| 2026-03-12 | Carr Douglas | Officer | S-Sale | D | Common Stock | 7,043 | 2.55 | 18.0K | 507,261 | D | ↗ |
| 2026-03-11 | Pfeiffenberger Brent | Director / Officer | F-InKind | D | Common Stock | 55,397 | 2.73 | 151.2K | 3,710,958 | D | ↗ |
| 2026-03-11 | Cowan Chad | Officer | F-InKind | D | Common Stock | 1,431 | 2.73 | 3.9K | 1,177,045 | D | ↗ |
| 2026-03-09 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 479 | 2.54 | 1.2K | 525,503 | D | ↗ |
| 2026-03-06 | Pfeiffenberger Brent | Director / Officer | F-InKind | D | Common Stock | 463 | 2.56 | 1.2K | 3,766,355 | D | ↗ |
| 2026-02-13 | Pfeiffenberger Brent | Director / Officer | F-InKind | D | Common Stock | 31,172 | 1.75 | 54.6K | 3,766,818 | D | ↗ |
| 2026-02-03 | Carr Douglas | Officer | S-Sale | D | Common Stock | 323 | 1.82 | 588.51 | 514,551 | D | ↗ |
| 2026-02-02 | Russotti Gregory | Officer | A-Award | A | Stock Option (right to buy) | 265,000 | 1.84 | 487.6K | 265,000 | D | ↗ |
| 2026-02-02 | Pfeiffenberger Brent | Director / Officer | A-Award | A | Stock Option (right to buy) | 945,000 | 1.84 | 1.74M | 945,000 | D | ↗ |
| 2026-02-02 | Cowan Chad | Officer | A-Award | A | Stock Option (right to buy) | 265,000 | 1.84 | 487.6K | 265,000 | D | ↗ |
| 2026-02-02 | Carr Douglas | Officer | A-Award | A | Stock Option (right to buy) | 225,000 | 1.84 | 414.0K | 225,000 | D | ↗ |
| 2026-01-02 | Cowan Chad | Officer | F-InKind | D | Common Stock | 1,611 | 1.00 | 1.6K | 1,043,476 | D | ↗ |
| 2025-12-22 | Cowan Chad | Officer | P-Purchase | A | Common Stock | 58,060 | 0.85 | 49.3K | 1,045,087 | D | ↗ |
| 2025-12-12 | Pfeiffenberger Brent | Director / Officer | P-Purchase | A | Common Stock | 52,000 | 0.58 | 30.4K | 3,322,990 | D | ↗ |
| 2025-12-10 | Pfeiffenberger Brent | Director / Officer | F-InKind | D | Common Stock | 463 | 0.53 | 243.54 | 3,270,990 | D | ↗ |
| 2025-12-09 | Murphy Martin Patrick | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-09 | Lee Han Myung | Director | A-Award | A | Stock Option (right to buy) | 88,000 | 0.59 | 52.1K | 88,000 | D | ↗ |
| 2025-12-08 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 526 | 0.53 | 279.83 | 390,982 | D | ↗ |
| 2025-12-08 | Carr Douglas | Officer | S-Sale | D | Common Stock | 257 | 0.53 | 136.72 | 404,874 | D | ↗ |
| 2025-11-20 | Cowan Chad | Officer | S-Sale | D | Common Stock | 5,462 | 0.50 | 2.7K | 987,027 | D | ↗ |
| 2025-11-19 | Pfeiffenberger Brent | Director / Officer | P-Purchase | A | Common Stock | 35,000 | 0.50 | 17.3K | 3,271,453 | D | ↗ |
| 2025-11-17 | Pfeiffenberger Brent | Director / Officer | S-Sale | D | Common Stock | 32,456 | 0.45 | 14.7K | 3,236,453 | D | ↗ |
| 2025-11-03 | Carr Douglas | Officer | S-Sale | D | Common Stock | 292 | 0.59 | 171.11 | 405,131 | D | ↗ |
| 2025-09-18 | Cowan Chad | Officer | A-Award | A | Common Stock | 762,543 | 0.00 | — | 992,489 | D | ↗ |
| 2025-09-08 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 539 | 0.50 | 269.50 | 391,508 | D | ↗ |
| 2025-09-08 | Pfeiffenberger Brent | Director / Officer | S-Sale | D | Common Stock | 488 | 0.50 | 244.00 | 3,268,909 | D | ↗ |
| 2025-09-08 | Carr Douglas | Officer | S-Sale | D | Common Stock | 263 | 0.50 | 131.50 | 405,423 | D | ↗ |
| 2025-08-14 | Pfeiffenberger Brent | Director / Officer | A-Award | A | Common Stock | 1,587,614 | 0.00 | — | 3,269,397 | D | ↗ |
| 2025-08-04 | Carr Douglas | Officer | S-Sale | D | Common Stock | 296 | 0.53 | 158.06 | 405,686 | D | ↗ |
| 2025-06-12 | Walbert Timothy P | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 0.60 | 26.4K | 44,000 | D | ↗ |
| 2025-06-12 | Riva Alessandro | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 0.60 | 26.4K | 44,000 | D | ↗ |
| 2025-06-12 | Quimi Daphne | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 0.60 | 26.4K | 44,000 | D | ↗ |
| 2025-06-12 | JIMENEZ JOSEPH | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 0.60 | 26.4K | 44,000 | D | ↗ |
| 2025-06-12 | Carlo Rizzuto | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 0.60 | 26.4K | 44,000 | D | ↗ |
| 2025-06-12 | Blackwell Kimberly | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 0.60 | 26.4K | 44,000 | D | ↗ |
| 2025-06-12 | BUTITTA CYNTHIA M | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 0.60 | 26.4K | 44,000 | D | ↗ |
| 2025-06-09 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 526 | 0.62 | 327.17 | 392,047 | D | ↗ |
| 2025-06-09 | Pfeiffenberger Brent | Director / Officer | S-Sale | D | Common Stock | 475 | 0.62 | 295.45 | 1,681,783 | D | ↗ |
| 2025-06-09 | Farid Adrienne | Officer | S-Sale | D | Common Stock | 552 | 0.62 | 343.34 | 250,141 | D | ↗ |
| 2025-06-09 | Carr Douglas | Officer | S-Sale | D | Common Stock | 4,904 | 0.62 | 3.1K | 405,982 | D | ↗ |
| 2025-05-16 | Pfeiffenberger Brent | Director / Officer | S-Sale | D | Common Stock | 29,552 | 0.55 | 16.1K | 1,682,258 | D | ↗ |
| 2025-05-05 | Farid Adrienne | Officer | S-Sale | D | Common Stock | 1,024 | 0.55 | 563.20 | 250,693 | D | ↗ |
| 2025-05-05 | Carr Douglas | Officer | S-Sale | D | Common Stock | 295 | 0.55 | 162.25 | 410,886 | D | ↗ |
| 2025-03-11 | Russotti Gregory | Officer | A-Award | A | Common Stock | 120,000 | 0.00 | — | 392,573 | D | ↗ |
| 2025-03-11 | Pfeiffenberger Brent | Director / Officer | A-Award | A | Stock Option (right to buy) | 521,500 | 0.60 | 313.4K | 521,500 | D | ↗ |
| 2025-03-11 | Farid Adrienne | Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 0.60 | 72.1K | 120,000 | D | ↗ |
| 2025-03-11 | Cowan Chad | Officer | A-Award | A | Stock Option (right to buy) | 19,500 | 0.60 | 11.7K | 19,500 | D | ↗ |
| 2025-03-11 | Conn Morgan | Officer | A-Award | A | Stock Option (right to buy) | 19,500 | 0.60 | 11.7K | 19,500 | D | ↗ |
| 2025-03-11 | Carr Douglas | Officer | A-Award | A | Common Stock | 95,625 | 0.00 | — | 411,181 | D | ↗ |
| 2025-03-10 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 2,360 | 0.62 | 1.5K | 272,573 | D | ↗ |
| 2025-03-10 | Pfeiffenberger Brent | Director / Officer | S-Sale | D | Common Stock | 2,235 | 0.62 | 1.4K | 1,190,310 | D | ↗ |
| 2025-03-10 | Farid Adrienne | Officer | S-Sale | D | Common Stock | 2,359 | 0.62 | 1.5K | 131,717 | D | ↗ |
| 2025-03-10 | Carr Douglas | Officer | S-Sale | D | Common Stock | 1,240 | 0.62 | 762.60 | 315,556 | D | ↗ |
| 2025-02-18 | Pfeiffenberger Brent | Director / Officer | S-Sale | D | Common Stock | 34,712 | 0.78 | 27.2K | 1,192,545 | D | ↗ |
| 2025-02-03 | Farid Adrienne | Officer | S-Sale | D | Common Stock | 1,054 | 0.78 | 822.12 | 134,076 | D | ↗ |
| 2025-02-03 | Carr Douglas | Officer | S-Sale | D | Common Stock | 351 | 0.78 | 273.78 | 316,796 | D | ↗ |
| 2024-12-04 | Pfeiffenberger Brent | Director / Officer | F-InKind | D | Common Stock | 243,447 | 1.44 | 350.6K | 1,227,257 | D | ↗ |
| 2024-11-04 | Farid Adrienne | Officer | S-Sale | D | Common Stock | 1,033 | 1.23 | 1.3K | 135,130 | D | ↗ |
| 2024-11-04 | Carr Douglas | Officer | S-Sale | D | Common Stock | 283 | 1.23 | 347.24 | 317,147 | D | ↗ |
| 2024-11-01 | Carr Douglas | Officer | F-InKind | D | Common Stock | 16,611 | 1.26 | 20.9K | 317,430 | D | ↗ |
| 2024-10-14 | Conn Morgan | Officer | A-Award | A | Stock Option (right to buy) | 360,890 | 1.48 | 534.1K | 360,890 | D | ↗ |
| 2024-10-01 | Cowan Chad | Officer | — | — | Common Stock | 0 | 0.00 | — | 10,697 | I | ↗ |
| 2024-09-12 | Quimi Daphne | Director | P-Purchase | A | Common Stock | 5,000 | 1.53 | 7.7K | 5,000 | — | ↗ |
| 2024-08-05 | Farid Adrienne | Officer | S-Sale | D | Common Stock | 1,073 | 1.83 | 2.0K | 136,163 | — | ↗ |
| 2024-08-05 | Carr Douglas | Officer | S-Sale | D | Common Stock | 289 | 1.83 | 528.00 | 334,041 | — | ↗ |
| 2024-07-26 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 586 | 2.50 | 1.5K | 274,933 | — | ↗ |
| 2024-07-24 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 1,600 | 2.52 | 4.0K | 275,519 | — | ↗ |
| 2024-07-23 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 200 | 2.50 | 500.00 | 277,119 | — | ↗ |
| 2024-06-20 | Walbert Timothy P | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 2.69 | 118.4K | 44,000 | — | ↗ |
| 2024-06-20 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 5,000 | 2.84 | 14.2K | 277,319 | — | ↗ |
| 2024-06-20 | Riva Alessandro | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 2.69 | 118.4K | 44,000 | — | ↗ |
| 2024-06-20 | Quimi Daphne | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 2.69 | 118.4K | 44,000 | — | ↗ |
| 2024-06-20 | JIMENEZ JOSEPH | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 2.69 | 118.4K | 44,000 | — | ↗ |
| 2024-06-20 | Carlo Rizzuto | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 2.69 | 118.4K | 44,000 | — | ↗ |
| 2024-06-20 | Blackwell Kimberly | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 2.69 | 118.4K | 44,000 | — | ↗ |
| 2024-06-20 | BUTITTA CYNTHIA M | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 2.69 | 118.4K | 44,000 | — | ↗ |
| 2024-06-07 | Carr Douglas | Officer | A-Award | A | Common Stock | 17,007 | 0.00 | — | 334,330 | — | ↗ |
| 2024-06-05 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 5,000 | 3.00 | 15.0K | 282,319 | — | ↗ |
| 2024-05-20 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 5,000 | 3.00 | 15.0K | 287,319 | — | ↗ |
| 2024-05-06 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 5,000 | 3.12 | 15.6K | 292,319 | — | ↗ |
| 2024-05-03 | Farid Adrienne | Officer | S-Sale | D | Common Stock | 913 | 3.11 | 2.8K | 137,236 | — | ↗ |
| 2024-05-03 | Carr Douglas | Officer | S-Sale | D | Common Stock | 257 | 3.11 | 798.24 | 317,323 | — | ↗ |
| 2024-04-22 | Russotti Gregory | Officer | S-Sale | D | Common Stock | 5,000 | 3.10 | 15.5K | 297,319 | — | ↗ |
| 2024-03-07 | Russotti Gregory | Officer | A-Award | A | Stock Option (right to buy) | 146,000 | 5.32 | 776.7K | 146,000 | — | ↗ |
| 2024-03-07 | Pfeiffenberger Brent | Director / Officer | A-Award | A | Stock Option (right to buy) | 104,550 | 5.32 | 556.2K | 104,550 | — | ↗ |
| 2024-03-07 | Levitsky Hyam | Officer | A-Award | A | Common Stock | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2024-03-07 | Farid Adrienne | Officer | S-Sale | D | Common Stock | 22,831 | 5.14 | 117.3K | 114,149 | — | ↗ |
| 2024-03-07 | Carr Douglas | Officer | A-Award | A | Stock Option (right to buy) | 81,000 | 5.32 | 430.9K | 81,000 | — | ↗ |
| 2024-03-06 | Farid Adrienne | Officer | M-Exempt | D | Stock Option (right to buy) | 30,684 | 1.03 | 31.6K | 191,486 | — | ↗ |
| 2024-02-16 | Farid Adrienne | Officer | M-Exempt | D | Stock Option (right to buy) | 485 | 1.03 | 499.55 | 222,170 | — | ↗ |
| 2024-02-06 | Farid Adrienne | Officer | S-Sale | D | Common Stock | 1,784 | 4.49 | 8.0K | 114,149 | — | ↗ |
| 2024-02-06 | Carr Douglas | Officer | S-Sale | D | Common Stock | 557 | 4.49 | 2.5K | 303,580 | — | ↗ |
| 2024-02-05 | Farid Adrienne | Officer | S-Sale | D | Common Stock | 2,035 | 3.84 | 7.8K | 115,933 | — | ↗ |
| 2024-02-05 | Carr Douglas | Officer | S-Sale | D | Common Stock | 643 | 3.84 | 2.5K | 304,137 | — | ↗ |
| 2023-12-04 | Pfeiffenberger Brent | Director / Officer | A-Award | A | Common Stock | 279,504 | 0.00 | — | 1,453,279 | — | ↗ |
| 2023-11-01 | Diem Michael Craig | Officer | F-InKind | D | Common Stock | 20,763 | 1.49 | 30.9K | 253,533 | — | ↗ |
| 2023-11-01 | Carr Douglas | Officer | F-InKind | D | Common Stock | 16,611 | 1.49 | 24.8K | 304,780 | — | ↗ |
| 2023-06-27 | Walbert Timothy P | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 3.19 | 140.4K | 44,000 | — | ↗ |
| 2023-06-27 | Riva Alessandro | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 3.19 | 140.4K | 44,000 | — | ↗ |
| 2023-06-27 | Quimi Daphne | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 3.19 | 140.4K | 44,000 | — | ↗ |
| 2023-06-27 | JIMENEZ JOSEPH | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 3.19 | 140.4K | 44,000 | — | ↗ |
| 2023-06-27 | Carlo Rizzuto | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 3.19 | 140.4K | 44,000 | — | ↗ |
| 2023-06-27 | Blackwell Kimberly | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 3.19 | 140.4K | 44,000 | — | ↗ |
| 2023-06-27 | BUTITTA CYNTHIA M | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 3.19 | 140.4K | 44,000 | — | ↗ |
| 2023-05-15 | Diem Michael Craig | Officer | A-Award | A | Common Stock | 151,058 | 0.00 | — | 274,296 | — | ↗ |
| 2023-05-15 | Carr Douglas | Officer | A-Award | A | Common Stock | 120,846 | 0.00 | — | 321,391 | — | ↗ |
| 2023-04-12 | Levitsky Hyam | Officer | A-Award | A | Stock Option (right to buy) | 131,250 | 2.91 | 381.9K | 131,250 | — | ↗ |
| 2023-04-11 | Russotti Gregory | Officer | A-Award | A | Stock Option (right to buy) | 318,750 | 3.16 | 1.01M | 318,750 | — | ↗ |
| 2023-04-03 | Borges Luis | Officer | M-Exempt | A | Common Stock | 7,452 | 1.03 | 7.7K | 256,535 | — | ↗ |
| 2023-03-23 | Borges Luis | Officer | M-Exempt | A | Common Stock | 220,930 | 1.03 | 227.6K | 264,680 | — | ↗ |
| 2023-03-22 | Borges Luis | Officer | M-Exempt | D | Stock Option (right to buy) | 65,698 | 1.03 | 67.7K | 228,382 | — | ↗ |
| 2023-03-21 | Borges Luis | Officer | M-Exempt | A | Common Stock | 63,616 | 1.03 | 65.5K | 107,366 | — | ↗ |
| 2023-02-02 | Russotti Gregory | Officer | A-Award | A | Stock Option (right to buy) | 175,000 | 4.64 | 812.0K | 175,000 | — | ↗ |
| 2023-02-02 | Flores Osvaldo | Officer | A-Award | A | Stock Option (right to buy) | 637,500 | 4.64 | 2.96M | 637,500 | — | ↗ |
| 2023-02-02 | Farid Adrienne | Officer | A-Award | A | Common Stock | 21,875 | 0.00 | — | 96,093 | — | ↗ |
| 2023-02-02 | Diem Michael Craig | Officer | A-Award | A | Common Stock | 21,875 | 0.00 | — | 101,363 | — | ↗ |
| 2023-02-02 | Carr Douglas | Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 4.64 | 208.8K | 45,000 | — | ↗ |
| 2023-02-02 | Borges Luis | Officer | A-Award | A | Common Stock | 21,875 | 0.00 | — | 21,875 | — | ↗ |
| 2022-10-01 | Walbert Timothy P | Director | A-Award | A | Stock Option (right to buy) | 39,744 | 0.00 | — | 39,744 | — | ↗ |
| 2022-10-01 | Quimi Daphne | Director | A-Award | A | Stock Option (right to buy) | 39,744 | 0.00 | — | 39,744 | — | ↗ |
| 2022-08-09 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 550,000 | 13.03 | 7.17M | 11,816,814 | — | ↗ |
| 2022-08-09 | Versant Vantage II GP-GP, LLC | Director | J-Other | D | Common Stock | 364,800 | 0.00 | — | 11,452,014 | — | ↗ |
| 2022-06-09 | Riva Alessandro | Director | A-Award | A | Stock Option (right to buy) | 19,872 | 0.00 | — | 19,872 | — | ↗ |
| 2022-06-09 | JIMENEZ JOSEPH | Director | A-Award | A | Stock Option (right to buy) | 19,872 | 0.00 | — | 19,872 | — | ↗ |
| 2022-06-09 | Casdin Eli | Director | A-Award | A | Stock Option (right to buy) | 19,872 | 0.00 | — | 19,872 | — | ↗ |
| 2022-06-09 | Carlo Rizzuto | Director | A-Award | A | Stock Option (right to buy) | 19,872 | 0.00 | — | 19,872 | — | ↗ |
| 2022-06-09 | Blackwell Kimberly | Director | A-Award | A | Stock Option (right to buy) | 19,872 | 0.00 | — | 19,872 | — | ↗ |
| 2022-06-09 | BUTITTA CYNTHIA M | Director | A-Award | A | Stock Option (right to buy) | 19,872 | 0.00 | — | 19,872 | — | ↗ |
| 2022-01-31 | Versant Venture Capital VI, L.P. | 10% Owner | J-Other | D | Common Stock | 178,996 | 0.00 | — | 12,366,814 | — | ↗ |
| 2022-01-25 | Russotti Gregory | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 13.15 | 1.38M | 105,000 | — | ↗ |
| 2022-01-25 | Levitsky Hyam | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 13.15 | 1.38M | 105,000 | — | ↗ |
| 2022-01-25 | Flores Osvaldo | Officer | A-Award | A | Stock Option (right to buy) | 315,000 | 13.15 | 4.14M | 315,000 | — | ↗ |
| 2022-01-25 | Farid Adrienne | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 13.15 | 1.38M | 105,000 | — | ↗ |
| 2022-01-25 | Diem Michael Craig | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 13.15 | 1.38M | 105,000 | — | ↗ |
| 2022-01-25 | Carr Douglas | Officer | A-Award | A | Stock Option (right to buy) | 35,000 | 13.15 | 460.3K | 35,000 | — | ↗ |
| 2022-01-25 | Borges Luis | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 13.15 | 1.38M | 105,000 | — | ↗ |
| 2021-12-23 | Versant Venture Capital VI, L.P. | 10% Owner | J-Other | D | Common Stock | 371,004 | 0.00 | — | 12,545,810 | — | ↗ |
| 2021-06-22 | Versant Venture Capital VI, L.P. | 10% Owner | C-Conversion | A | Common Stock | 9,936,011 | 0.00 | — | 12,916,814 | — | ↗ |
| 2021-06-22 | FUJIFILM Cellular Dynamics, Inc. | 10% Owner | C-Conversion | D | Series A Convertible Preferred Stock | 10,000,000 | 0.00 | — | 0 | — | ↗ |
| 2021-06-22 | Casdin Eli | Director | C-Conversion | A | Common Stock | 2,456,380 | 0.00 | — | 2,456,380 | — | ↗ |
| 2021-06-22 | BAYER AKTIENGESELLSCHAFT | 10% Owner | C-Conversion | D | Series B Preferred Stock | 26,143,790 | 0.00 | — | 0 | — | ↗ |
| 2021-06-17 | Versant Venture Capital VI, L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,980,803 | — | ↗ |
| 2021-06-17 | Russotti Gregory | Officer | — | I | Common Stock | 0 | 0.00 | — | 92,773 | — | ↗ |
| 2021-06-17 | Riva Alessandro | Director | — | D | Stock Option (right to buy) | 99,483 | 7.27 | 723.2K | 0 | — | ↗ |
| 2021-06-17 | Levitsky Hyam | Officer | — | I | Common Stock | 0 | 0.00 | — | 536,544 | — | ↗ |
| 2021-06-17 | JIMENEZ JOSEPH | Director | — | D | Common Stock | 0 | 0.00 | — | 494,346 | — | ↗ |
| 2021-06-17 | Flores Osvaldo | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 526,839 | — | ↗ |
| 2021-06-17 | Farid Adrienne | Officer | — | D | Common Stock | 0 | 0.00 | — | 74,218 | — | ↗ |
| 2021-06-17 | FUJIFILM Cellular Dynamics, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,980,803 | — | ↗ |
| 2021-06-17 | Diem Michael Craig | Officer | — | D | Common Stock | 0 | 0.00 | — | 79,488 | — | ↗ |
| 2021-06-17 | Casdin Eli | Director | D-Return | A | Option (right to buy) | 39,744 | 20.00 | 794.9K | 39,744 | — | ↗ |
| 2021-06-17 | Carr Douglas | Officer | — | D | Common Stock | 0 | 0.00 | — | 203,430 | — | ↗ |
| 2021-06-17 | Carlo Rizzuto | Director | A-Award | A | Option (right to buy) | 39,744 | 20.00 | 794.9K | 39,744 | — | ↗ |
| 2021-06-17 | Borges Luis | Officer | — | D | Stock Option (right to buy) | 146,826 | 7.27 | 1.07M | 0 | — | ↗ |
| 2021-06-17 | Blackwell Kimberly | Director | A-Award | A | Option (right to buy) | 19,872 | 20.00 | 397.4K | 19,872 | — | ↗ |
| 2021-06-17 | BUTITTA CYNTHIA M | Director | A-Award | A | Option (right to buy) | 19,872 | 20.00 | 397.4K | 19,872 | — | ↗ |
| 2021-06-17 | BAYER AKTIENGESELLSCHAFT | 10% Owner | — | D | Series B Preferred Stock | 10,390,600 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-107.4K
Shares Outstanding
86.57M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Brent Pfeiffenberger, Pharm.D., President, Chief Executive Officer and Chairman of the Board | 640.6K | — | 1.87M | 222.7K | 317.1K | 14.0K | 2.38M | 87.87% | ↗ |
| 2 | 2025 | Chad Cowan , Ph.D. , Chief Scientific Officer | 559.5K | — | 398.3K | 8.3K | 201.0K | — | 1.17M | 34.85% | ↗ |
| 3 | 2025 | Adrienne Farid, Ph.D., Former Chief Development Officer | 333.3K | — | 71.1K | 51.2K | — | 533.5K | 989.4K | 12.37% | ↗ |
| 4 | 2025 | Gregory Russotti, Ph.D., Chief Technology and Manufacturing Officer and former Interim President and Chief Executive Officer | 559.7K | — | 71.1K | 51.2K | 226.7K | 3.7K | 912.3K | 13.41% | ↗ |
| 5 | 2024 | Brent Pfeiffenberger, Pharm.D., President and Chief Executive Officer | 625.0K | 450.0K | 92.6K | 392.0K | 360.9K | 272.7K | 2.19M | 22.10% | ↗ |
| 6 | 2024 | Brent Pfeiffenberger, Pharm.D., President, Chief Executive Officer and Chairman of the Board | 625.0K | 450.0K | 92.6K | 392.0K | 360.9K | 272.7K | 2.19M | 22.10% | ↗ |
| 7 | 2024 | Gregory Russotti, Ph.D., Chief Technology and Manufacturing Officer and former Interim President and Chief Executive Officer | 542.5K | — | 127.6K | 547.4K | 256.3K | 13.8K | 1.49M | 45.37% | ↗ |
| 8 | 2024 | Adrienne Farid, Ph.D., Chief Development Officer | 513.1K | — | 127.6K | 547.4K | 215.5K | 13.8K | 1.42M | 47.62% | ↗ |
| 9 | 2024 | Adrienne Farid, Ph.D., Former Chief Development Officer | 513.1K | — | 127.6K | 547.4K | 215.5K | 13.8K | 1.42M | 47.62% | ↗ |
| 10 | 2023 | Osvaldo Flores, Ph.D. Former President and Chief Executive Officer | 176.0K | — | — | 4.19M | — | 634.1K | 4.98M | 84.13% | ↗ |
| 11 | 2023 | Brent Pfeiffenberger, Pharm.D., President and Chief Executive Officer | 49.7K | 200.0K | 2.34M | 621.2K | 24.3K | — | 3.24M | 91.53% | ↗ |
| 12 | 2023 | Gregory Russotti, Ph.D., Chief Technology and Manufacturing Officer and former Interim President and Chief Executive Officer | 564.4K | — | — | 1.74M | 275.0K | 13.2K | 2.59M | 67.08% | ↗ |
| 13 | 2023 | Michael Diem, M.D., former Chief Financial Officer | 490.4K | — | 703.0K | 836.6K | 182.6K | 13.2K | 2.23M | 69.17% | ↗ |
| 14 | 2023 | Adrienne Farid, Ph.D. Chief Operations Officer | 490.4K | — | 203.0K | 836.6K | 166.7K | 13.2K | 1.71M | 60.80% | ↗ |
| 15 | 2023 | Adrienne Farid, Ph.D., Chief Development Officer | 490.4K | — | 203.0K | 836.6K | 166.7K | 13.2K | 1.71M | 60.80% | ↗ |
| 16 | 2022 | Osvaldo Flores, Ph.D. Former President and Chief Executive Officer | 580.2K | — | — | 2.71M | 290.1K | — | 3.58M | 75.67% | ↗ |
| 17 | 2022 | Adrienne Farid, Ph.D. Chief Operations Officer | 456.0K | — | — | 902.3K | 182.4K | 12.2K | 1.55M | 58.10% | ↗ |
| 18 | 2022 | Michael Diem, M.D. Chief Financial Officer | 456.0K | — | — | 902.3K | 182.4K | 12.2K | 1.55M | 58.10% | ↗ |
| 19 | 2022 | Michael Diem, M.D., former Chief Financial Officer | 456.0K | — | — | 902.3K | 182.4K | 12.2K | 1.55M | 58.10% | ↗ |
| 20 | 2021 | Osvaldo Flores, Ph.D. Former President and Chief Executive Officer | 519.3K | — | — | 3.54M | 258.7K | — | 4.32M | 81.98% | ↗ |
| 21 | 2021 | Osvaldo Flores, Ph.D. President and Chief Executive Officer | 519.3K | — | — | 3.54M | 258.7K | — | 4.32M | 81.98% | ↗ |
| 22 | 2021 | Adrienne Farid, Ph.D. Chief Operations Officer | 416.4K | — | — | 945.3K | 161.5K | 11.6K | 1.53M | 61.59% | ↗ |
| 23 | 2021 | Luis Borges, Ph.D. Chief Science Officer | 427.7K | — | — | 668.4K | 164.8K | 11.6K | 1.27M | 52.53% | ↗ |
| 24 | 2021 | Michael Diem, M.D. Chief Financial Officer | 437.8K | — | — | 579.0K | 191.2K | 11.6K | 1.22M | 47.47% | ↗ |
| 25 | 2020 | Osvaldo Flores, Ph.D. President and Chief Executive Officer | 461.3K | — | — | 741.8K | 185.4K | — | 1.39M | 53.42% | ↗ |
| 26 | 2020 | Adrienne Farid, Ph.D. Chief Operations Officer | 379.3K | — | — | 78.9K | 114.3K | 11.4K | 583.9K | 13.51% | ↗ |
| 27 | 2020 | Luis Borges, Ph.D. Chief Science Officer | 410.0K | — | — | — | 123.6K | 11.4K | 545.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brent Pfeiffenberger | President, Chief Executive Officer & Chairman | 971.7K | male |
| Gregory Russotti | Chief Technology & Manufacturing Officer | 790.0K | — |
| Chad A. Cowan | Chief Scientific Officer | 760.5K | — |
| Douglas Carr | Senior VP of Finance & Operations, Principal Financial Officer and Secretary | — | male |
| Elizabeth Devlin | Vice President & Head of Development | — | female |
| Krista Kauppinen | VP, General Counsel & Head of Intellectual Property | — | — |
| Megan Bilson | Chief People Officer | — | female |
| Michael Naso | Senior Vice President of Cell Engineering | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IPSC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
